Percutaneous Coronary Interventions Affect Concentrations of Interleukin 6 and Its Soluble Receptors in Coronary Sinus Blood in Patients with Stable Angina
Restricted accessResearch articleFirst published online June, 2009
Percutaneous Coronary Interventions Affect Concentrations of Interleukin 6 and Its Soluble Receptors in Coronary Sinus Blood in Patients with Stable Angina
Coronary stenting may create local inflammatory reaction. Interleukin 6 effects depend on the presence of soluble receptors (sIL-6R and sgp130) that facilitate or impede interleukin 6 signal transduction. Concentrations of interleukin 6 and its soluble receptors were assessed in aorta and coronary sinus after stenting in optimally treated stable angina patients scheduled for elective stenting. Baseline levels of interleukin 6 and its soluble receptors in patients did not differ from healthy controls. Initial levels of sIL-6R in aorta were significantly higher than in coronary sinus but this difference disappeared after intervention. Stenting caused interleukin 6 concentration increase to a similar extent both in coronary sinus and in aorta. Moreover, there was significantly higher sgp130 concentration in coronary sinus than in aorta. Coronary intervention increases concentration of interleukin 6 in patients with stable angina. It affects the cardiac level of interleukin 6 soluble receptors what may influence the local inflammatory reaction.
LiJ.J., QinX.W., YangX.C.Randomized comparison of early inflammatory response after sirolimus-eluting stent vs bare metal stent implantation in native coronary lesions.Clin Chim Acta.2008; 396: 38–42.
2.
FerreroV., RibichiniF., PesariniG., BrunelleschiS., VassanelliC.Glucocorticoids in the prevention of restenosis after coronary angioplasty: therapeutic potential.Drugs.2007; 67: 1243–1255.
3.
KanjilalS., ShankerJ., RaoV.S.Association of metabolic syndrome with atherothrombotic blood phenotypes in Asian Indian families with premature coronary artery disease.Arch Med Sci. 2008; 4: 145–151.
4.
KopfM., BaumannH., FreerG.Impaired immune and acute-phase responses in interleukin-6-deficient mice.Nature.1994; 368: 339–342.
5.
SchiefferB., SelleT., HilfikerA.Impact of interleukin-6 on plaque development and morphology in experimental atherosclerosis.Circulation.2004; 110: 3493–3500.
6.
DawnB., XuanY.T., GuoY.IL-6 plays an obligatory role in late preconditioning via JAK-STAT signaling and upregulation of iNOS and COX-2.Cardiovasc Res.2004; 64: 61–71.
7.
Rose-JohnS., SchellerJ., ElsonG.Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer.J Leukoc Biol.2006; 80: 227–236.
8.
Rose-JohnS., WaetzigG.H., SchellerJ., GrötzingerJ., SeegertD.The IL-6/sIL-6R complex as a novel target for therapeutic approaches.Expert Opin Ther Targets.2007; 11: 613–624.
9.
HojoY., IkedaU., KatsukiT.Interleukin 6 expression in coronary circulation after coronary angioplasty as a risk factor for restenosis.Heart.2000; 84: 83–87.
10.
BossowskaA., Kiersnowska-RogowskaB., BossowskiA.Cytokines in patients with ischaemic heart disease or myocardial infarction.Kardiol Pol.2003; 59: 105–114.
11.
KinlayS., SchwartzG.G., OlssonA.G.Inflammation, statin therapy, and risk of stroke after an acute coronary syndrome in the MIRACL study.Arterioscler Thromb Vasc Biol.2008; 28: 142–147.
12.
KowalskiJ., BarylskiM., BanachM., GrycewiczJ., IrzmanskiR., PawlickiL.Neutrophil superoxide anion generation during atorvastatin and fluvastatin therapy used in coronary heart disease primary prevention.J Cardiovasc Pharmacol.2006; 48: 143–147.
13.
AthyrosV.G., KakafikaA.I., KaragiannisA., MikhailidisD.P.Do we need to consider inflammatory markers when we treat atherosclerotic disease?Atherosclerosis.2008; 200: 1–12.
14.
ReferJ.M., GalantiL.M., DesmetS.Time course of release of inflammatory markers after coronary stenting: comparison between bare metal stent and sirolimuseluting stent.Coron Artery Dis.2005; 16: 505–509.
15.
SardellaG., MarianiP., D'AlessandroM.Early elevation of interleukin-lbeta and interleukin-6 levels after bare or drug-eluting stent implantation in patients with stable angina.Thromb Res.2006; 117: 659–664.
16.
IchikiT., JougasakiM., SetoguchiM.Plasma levels of soluble glycoprotein 130 in acute myocardial infarction.Cardiol.2007; 50: 101–109.
17.
HirotaH., IzumiM., HamaguchiT.Circulating interleukin-6 family cytokines and their receptors in patients with congestive heart failure.Heart Vessels.2004; 19: 237–241.
18.
DetenA., VolzH.C., BriestW., ZimmerH.G.Cardiac cytokine expression is upregulated in the acute phase after myocardial infarction. Experimental studies in rats.Cardiovasc Res.2002; 55: 329–340.
19.
MemoliB., GrandalianoG., SoccioM.In vivo modulation of soluble “antagonistic” IL-6 receptor synthesis and release in ESRD.J Am Soc Nephrol.2005; 16: 1099–1107.
20.
SchipkeJ.D., HalkosM.E., KerendiF., GamsE., Vinten-JohansenJ.Postconditioning: a brief review.Arch Med Sci.2006; 2: 137–145.
21.
BoenglerK., BuechertA., HeinenY.Cardioprotection by ischemic postconditioning is lost in aged and STAT3-deficient mice.Circ Res.2008; 102: 131–135.
22.
OkaH., IkedaS., KogaS., MiyaharaY., KohnoS.Atorvastatin induces associated reductions in platelet P-selectin, oxidized low-density lipoprotein, and interleukin-6 in patients with coronary artery diseases.Heart Vessels.2008; 23: 249–256.
23.
TsitourasP.D., GucciardoF., SalbeA.D., HewardC., HarmanS.M.High omega-3 fat intake improves insulin sensitivity and reduces CRP and IL6, but does not affect other endocrine axes in healthy older adults.Horm Metab Res.2008; 40: 199–205.
24.
KowalskiJ., BanachM., BarylskiM., IrzmanskiR., PawlickiL.Carvedilol modifies antioxidant status of patients with stable angina.Cell Mol Biol Lett.2008; 13: 230–239.
25.
MerinoA., GayáA., SeguraI., CalvoJ., ImízcozC., BerenguelA., AlegríaE.Platelet aggregation inhibition blocks C-reactive protein and interleukin-6 (IL-6) elevation after the coronary angioplasty: effect of the −174 G/C IL-6 gene polymorphism.Am J Cardiol.2004; 94: 1300–1303.
